Vasodilation to PTH (1-84) in bone arteries is dependent upon the vascular endothelium and is mediated partially via VEGF signaling

Bone

Volumn 54, Issue 1, 2013, Pages 68-75

  Prisby, Rhonda ^a   Menezes, Thomas ^b   Campbell, Jeremiah ^b  

^a UNIVERSITY OF DELAWARE   (United States)

^b UNIVERSITY OF TEXAS AT ARLINGTON   (United States)

Author keywords

Bevacizumab; Bone formation; Bone vascular function; PTH; VEGF

Indexed keywords

ACETYLCHOLINE; INDOMETACIN; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITROPRUSSIDE SODIUM; PARATHYROID HORMONE; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERY DILATATION; ARTICLE; BONE MASS; BONE REMODELING; CELL ACTIVITY; CONTROLLED STUDY; DRUG INTERMITTENT THERAPY; FEMORAL ARTERY; FEMORAL PRINCIPAL NUTRIENT ARTERY; MALE; MUSCULOSKELETAL SYSTEM PARAMETERS; NONHUMAN; OSSIFICATION; OSTEOCLAST; RAT; SIGNAL TRANSDUCTION; TRABECULAR BONE; UPREGULATION; VASCULAR ENDOTHELIUM;

ACETYLCHOLINE; ANIMALS; ANTIBODIES; ARTERIES; BIOMECHANICAL PHENOMENA; BONE REMODELING; CYCLOOXYGENASE INHIBITORS; ENDOTHELIUM, VASCULAR; FEMUR; MALE; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; NITROPRUSSIDE; PARATHYROID HORMONE; RATS; RATS, WISTAR; REGRESSION ANALYSIS; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASODILATION; VASODILATOR AGENTS;

EID: 84873928461     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2013.01.028     Document Type: Article

References (43)

1. Kapitola J., Zák J. Effect of parathormone on bone blood flow in rats-possible role of NO. Sb Lek 2003, 104:133-137.
2. Boelkins J., Mazurkiewicz M., Mazur P.E., Mueller W.J. Changes in blood flow to bones during the hypocalcemic and hypercalcemic phases of the response to parathyroid hormone. Endocrinology 1976, 98:403-412.
3. Charbon G., Brummer F., Reneman R.S. Diuretic and vascular action of parathyroid extracts in animals and man. Arch Int Pharmacodyn Ther 1968, 171:1-11.
4. Charbon G. Vasodilator action of parathyroid hormone used as bioassay. Arch Int Pharmacodyn Ther 1969, 178:296-303.
5. Charbon G., Hulstaert P.F. Augmentation of arterial hepatic and renal flow by extracted and synthetic parathyroid hormone. Endocrinology 1974, 95:621-626.
6. Pang P., Yang M.C., Shew R., Tenner T.E. The vasorelaxant action of parathyroid hormone fragments on isolated rat tail artery. Blood Vessels 1985, 22:57-64.
7. Nickols G. Actions of parathyroid hormone in the cardiovascular system. Blood Vessels 1987, 24:120-124.
8. Nickols G., Metz M.A., Cline W.H. Endothelium-independent linkage of parathyroid hormone receptors of rat vascular tissue with increased adenosine 3?,5?-monophosphate and relaxation of vascular smooth muscle. Endocrinology 1986, 119:349-356.
9. Crass M.R., Hulsey S.M., Bulkley T.J. Use of a new pulsatile perfused rat aorta preparation to study the characteristics of the vasodilator effect of parathyroid hormone. J Pharmacol Exp Ther 1988, 245:723-734.
10. Nickols G., Metz M.A., Cline W.H. Vasodilation of the rat mesenteric vasculature by parathyroid hormone. J Pharmacol Exp Ther 1986, 236:419-423.
11. Pang P., Janssen H.F., Yee J.A. Effects of synthetic parathyroid hormone on vascular beds of dogs. Pharmacology 1980, 21:213-222.
12. Driessens M., Vanhoutte P.M. Effect of calcitonin, hydrocortisone, and parathyroid hormone on canine bone blood vessels. Am J Physiol 1981, 241:H91-H94.
13. Esbrit P., Alvarez-Arroyo M.V., De Miguel F., Martin O., Martinez M.E., Caramelo C. C-terminal parathyroid hormone-related protein increases vascular endothelial growth factor in human osteoblastic cells. J Am Soc Nephrol 2000, 11:1085-1092.
14. Prisby R., Guignandon A., Vanden-Bossche A., Mac-Way F., Linossier M.T., Thomas M., et al. Intermittent PTH (1-84) is osteoanabolic but not osteoangiogenic and relocates bone marrow blood vessels closer to bone-forming sites. J Bone Miner Res 2011, 26:2583-2596.
15. Eckardt H., Bundgaard K.G., Christensen K.S., Lind M., Hansen E.S., Hvid I. Effects of locally applied vascular endothelial growth factor (VEGF) and VEGF inhibitor to the rabbit tibia during distraction osteogenesis. J Orthop Res 2003, 21:335-340.
16. Brookes M., Revell W.J. Blood Supply of Bone 1998, Springer, London, Great Britain.
17. Prisby R., Ramsey M.W., Behnke B.J., Dominguez J.M., Donato A.J., Allen M.R., et al. Aging reduces skeletal blood flow, endothelium-dependent vasodilation and nitric oxide bioavailability in rats. J Bone Miner Res 2007, 22:1280-1288.
18. Verhaar H., Lems W.F. PTH-analogs: comparable or different. Arch Gerontol Geriatr 2009, 49:e130-e132.
19. Neuprez A., Reginster J.Y. Bone-forming agents in the management of osteoporosis. Best Pract Res Clin Endocrinol Metab 2008, 22:869-883.
20. Colleran P., Wilkerson M.K., Bloomfield S.A., Suva L.J., Turner R.T., Delp M.D. Alterations in skeletal perfusion with simulated microgravity: a possible mechanism for bone remodeling. J Appl Physiol 2000, 89:1046-1054.
21. Collin-Osdoby P. Role of vascular endothelial cells in bone biology. J Cell Biochem 1994, 55:304-309.
22. Kasten T., Collin-Osdoby P., Patel N., Osdoby P., Krukowski M., Misko T.P., et al. Potentiation of osteoclast bone-resorption activity by inhibition of nitric oxide synthase. Proc Natl Acad Sci U S A 1994, 91:3569-3573.
23. MacIntyre I., Zaidi M., Alam A.S., Datta H.K., Moonga B.S., Lidbury P.S., et al. Osteoclastic inhibition: an action of nitric oxide not mediated by cyclic GMP. Proc Natl Acad Sci U S A 1991, 88:2936-2940.
24. Johnson D., McAllister T.N., Frangos J.A. Fluid flow stimulates rapid and continuous release of nitric oxide in osteoblasts. Am J Physiol 1996, 271:E205-E208.
25. Jüppner H., Abou-Samra A.B., Freeman M., Kong X.F., Schipani E., Richards J., et al. A G protein-linked receptor for parathyroid hormone and parathyroid hormone related peptide. Science 1991, 254:1024-1026.
26. Rashid G., Bernheim J., Green J., Benchetrit S. Parathyroid hormone stimulates the endothelial nitric oxide synthase through protein kinase A and C pathways. Nephrol Dial Transplant 2007, 10:2831-2837.
27. Bisello A., Friedman P.A. PTH and PTHrP actions on kidney and bone. Principles of bone biology 2008, 665-712. Elsevier, California. J. Bilezikian, L.G. Raisz, T.J. Martin (Eds.).
28. Pang P., Yang M.C., Tenner T.E., Kenny A.D., Cooper C.W. Cyclic AMP and the vascular action of parathyroid hormone. Can J Physiol Pharmacol 1986, 64:1543-1547.
29. Mok L., Nickols G.A., Thompson J.C., Cooper C.W. Parathyroid hormone as a smooth muscle relaxant. Endocr Rev 1989, 10:420-436.
30. Nickols G. Increased cyclic AMP in cultured vascular smooth muscle cells and relaxation of aortic strips by parathyroid hormone. Eur J Pharmacol 1985, 116:137-144.
31. Isales C., Sumpio B., Bollag R.J., Zhong Q., Ding K.H., Du W., et al. Functional parathyroid hormone receptors are present in an umbilical vein endothelial cell line. Am J Physiol Endocrinol Metab 2000, 279:E654-E662.
32. Throckmorton D., Kurscheid-Reich D., Rosales O.R., Rodriguez-Commes J., Lopez R., Sumpio B., et al. Parathyroid hormone effects on signaling pathways in endothelial cells vary with peptide concentration. Peptides 2002, 23:79-85.
33. Kalinowski L., Dobrucki L.W., Malinski T. Nitric oxide as a second messenger in parathyroid hormone-related protein signaling. J Endocrinol 2001, 170:433-440.
34. Dominguez J., Prisby R.D., Muller-Delp J.M., Allen M.R., Delp M.D. Increased nitric oxide-mediated vasodilation of bone resistance arteries is associated with increased trabecular bone volume after endurance training in rats. Bone 2010, 46:813-819.
35. Prisby R.D., Muller-Delp J., Delp M.D., Nurkiewicz T.R. Age, gender and hormonal status modulate the vascular toxicity of the diesel exhaust extract phenanthraquinone. J Toxicol Environ Health A 2008, 71:464-470.
36. Deckers M., Karperien M., van der Bent C., Yamashita T., Papapoulos S.E., Lowik C.W. Expression of vascular endothelial growth factors and their receptors during osteoblast differentiation. Endocrinology 2000, 141:1667-1674.
37. Maes C., Carmeliet G. Vascular and nonvascular roles of VEGF in bone development. VEGF in development 2008, 79-90. Springer, Austin. C. Ruhrberg (Ed.).
38. Zelzer E., McLean W., Ng Y.S., Fukai N., Reginato A.M., Lovejoy S., et al. Skeletal defects in VEGF (120/120) mice reveal multiple roles for VEGF in skeletogenesis. Development 2002, 129:1893-1904.
39. Street J., Bao M., deGuzman L., Bunting S., Peale F.V., Ferrara N., et al. Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover. Proc Natl Acad Sci U S A 2002, 99:9656-9661.
40. Deckers M., Karperien M., van der Bent C., Yamashita T., Papapoulos S.E., Löwik C.W. Expression of vascular endothelial growth factors and their receptors during osteoblast differentiation. Endocrinology 2000, 141:1667-1674.
41. Fukumura D., Gohongi T., Kadambi A., Izumi Y., Ang J., Yun C.O., et al. Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. Proc Natl Acad Sci U S A 2001, 98:2604-2609.
42. Mourad J., des Guetz G., Debbabi H., Levy B.I. Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann Oncol 2008, 19:927-934.
43. Ziche M., Morbidelli L., Choudhuri R., Zhang H.T., Donnini S., Granger H.J., et al. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J Clin Invest 1997, 99:2625-2634.